<DOC>
	<DOC>NCT00463268</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of the intermittent administration of alendronate in a low dose, 70 mg once every two week, as osteoporosis prevention for menopausal, osteopenic patients, who don't want or can't receive an oestrogenic substitution treatment.</brief_summary>
	<brief_title>Osteoporosis Prevention With Low Dose Alendronate</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>45 to 60 yearold women Menopausal since at least 6 months Baseline lumbar BMD from 1 till 2.5 Bone disease other than osteopenia Treatment with selective estrogen receptor modulator (SERMs), calcitonin or hormone replacement therapy within 6 monts prior to randomization Former or current treatment with any bisphosphonate or bone forming agents Chronic use of oral or iv corticosteroids Any diagnosis of malignancy less than 12 months</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>osteopenia</keyword>
	<keyword>osteoporosis prevention</keyword>
	<keyword>alendronate</keyword>
</DOC>